Cynvenio Biosystems PD-L1 Expression Assay
Cynvenio Biosystems has launched its second-generation PD-L1 expression test. The blood test has improved analytic performance compared to the first-generation test, enabling highly sensitive and specific profiling and monitoring of PD-L1 expression on lung cancer cells recovered from blood. Cynvenio is offering the test from its CLIA/CAP laboratory in California with a three- to seven-day turnaround time. The test is also available to all Cynvenio customers running its LiquidBiopsy platform and workflow, the company said.